A Systematic Review on the In Vivo Studies on Radiofrequency (100 kHz–300 GHz) Electromagnetic Field Exposure and Co-Carcinogenesis, Pinto, Rosanna, Ardoino Lucia, Giardullo Paola, Villani Paola, and Marino Carmela , International Journal of Environmental Research and Public Health, Volume 21, Number 8, (2024)

A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers, Bissa, M., Illiano E., Pacchioni S., Paolini F., Zanotto C., C. Morghen De Giuli, Massa Silvia, Franconi Rosella, Radaelli A., and Venuti A. , Journal of Translational Medicine, Volume 13, Number 1, (2015)

The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors, Kondo, K., Van Schil P., Detterbeck F.C., Okumura M., Giroux D., Asamura H., Crowley J., Falkson C., Filosso P.L., Giaccone G., et al. , Journal of Thoracic Oncology, Volume 9, Number 9, p.S81-S87, (2014)

An E7-based therapeutic vaccine protects mice against HPV16 associated cancer, Venuti, A., Massa Silvia, Mett V., Vedova L.D., Paolini F., Franconi Rosella, and Yusibov V. , Vaccine, Volume 27, Number 25-26, p.3395-3397, (2009)

Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma, Diomedi-Camassei, F., McDowell H.P., De loris M.A., Uccini S., Altavista P., Raschellà G., Vitali Roberta, Mannarino O., De Sio L., Cozzi D.A., et al. , Clinical Cancer Research, Volume 14, Number 13, p.4119-4127, (2008)

Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer, Bria, E., Visca P., Novelli Flavia, Casini B., Diodoro M.G., Perrone-Donnorso R., Botti C., Sperduti I., Facciolo F., Milella M., et al. , European Journal of Surgical Oncology, Volume 34, Number 5, p.593-598, (2008)

Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: Multivariate analysis of prognostic factors, Nisticò, C., Cuppone F., Bria E., Fornier M., Giannarelli D., Mottolese M., Novelli Flavia, Natoli G., Cognetti F., and Terzoli E. , Anti-Cancer Drugs, Volume 17, Number 10, p.1193-1200, (2006)

Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors, Uccini, S., Mannarino O., McDowell H.P., Pauser U., Vitali Roberta, Natali P.G., Altavista P., Andreano T., Coco S., Boldrini R., et al. , Clinical Cancer Research, Volume 11, Number 1, p.380-389, (2005)

Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy, Piperno, G., Cosimelli M., Donnorso R.P., Mancini R., Buglioni S., Novelli Flavia, Sperduti I., Zerbini V., Garufi C., and Mottolese M. , Journal of Chemotherapy, Volume 16, Number SUPPL. 5, p.11-14, (2004)

Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification, Raschellà, G., Cesi Vincenzo, Amendola R., Negroni Anna, Tanno Barbara, Altavista P., Tonini G.P., De Bernardi B., and Calabretta B. , Cancer Research, Volume 59, Number 14, p.3365-3368, (1999)